SSDP Advocates for Science-Based Approaches to 7-OH and Kratom Policy

Students for Sensible Drug Policy recently hosted “Kratom, 7-OH, and Emerging Products: A Science-Based Safety Primer,” a webinar focused on the growing conversations around kratom-derived products, 7-hydroxymitragynine (7-OH), public health concerns, and evidence-based regulation. The event brought together experts and advocates to discuss current research, potential risks, harm reduction strategies, and the importance of nuanced education as policymakers debate new restrictions on these substances.

The conversation closely connects to SSDP’s recent statement opposing the proposed END 7-OH Act (H.R. 8000), which would classify synthetic 7-OH as a Schedule I controlled substance. SSDP argues that broad criminalization could undermine scientific research, limit exploration of possible therapeutic uses, and push consumers toward unregulated markets rather than improving safety outcomes. Instead, SSDP supports evidence-based safeguards such as product testing, accurate labeling, age restrictions, and quality control standards.

As debates around kratom and emerging products continue nationwide, SSDP remains committed to promoting harm reduction, scientific integrity, and policies grounded in public health rather than fear or stigma.